Top NYC, NY Social Impact Companies With Best Stability & Growth (532)

Strong Revenue Growth: Revenue is consistently rising at double-digit rates, including about 26% growth in 2025 and 22%–28% year-over-year gains across early 2026. Company disclosures also highlight increasing payers and monetization, reinforcing the revenue trajectory.

Market Expansion: International rollout accelerated across Europe and Latin America in 2025–2026, with entries into additional countries and leadership in downloads across several expansion markets. European expansion-market revenue rose sharply year over year, evidencing traction beyond core English-speaking geographies.

Strong Market Position & Advantage: The app maintains a top-tier standing among dating platforms, including #1 download positions in select European markets and a top-three rank in the U.S. Consistent MAU and payer growth alongside high download ranks indicate strengthening competitive footing.

Market Expansion: National and payer footprint have broadened materially, with availability across all 50 states, plan relationships rising toward 100+, and sharp increases in providers, patients, and appointments. This widening reach indicates an ability to capture demand across geographies and insurance lines.

Investor Backing & Capital Strength: A $100M Series D at a roughly $2.3B valuation alongside substantial prior financing reflects strong access to growth capital. This position supports continued scaling of the network, product investments, and deeper insurer integrations.

Strong Revenue Growth: Revenue is described as having increased significantly over a recent 12‑month period, with earlier disclosures citing outsized year‑over‑year gains. Coupled with rising session volumes, this points to robust top‑line momentum despite limited public financial detail.

Strong Revenue Growth: Revenue is depicted as rising dramatically, including an increase from $3.6M in 2021 to $617.4M in 2024 and subsequent commentary citing a roughly $1B run rate.

Investor Backing & Capital Strength: Capital access appears robust, highlighted by a $150M Series D in 2026 at an approximately $3B valuation and total funding near $328M from prominent investors.

Market Expansion: Geographic and channel reach is expanding, with 26,000+ clinicians across all 50 states, 125+ insurance partners (including Medicare and Medicaid), and movement into employer and health‑system partnerships.

Product Line Growth: Newer businesses such as Pharma Direct and subscriptions are expanding rapidly, with clear momentum highlighted in 2026. Investment is being shifted toward these lines to replace slower legacy revenue.

Future-Ready Strategy: Management is prioritizing Pharma Direct and subscription products and raised 2026 revenue guidance, signaling a transition aimed at restoring overall growth. These segments are described as the main engines expected to offset declines in the legacy business.

Profitability: Profitability remains solid even as the top line fluctuates, including positive GAAP earnings and substantial adjusted EBITDA in Q2 2026. Operating cash flow also strengthened, supporting continued execution.

Market Expansion: Geographic reach is described as nationwide through Medicare, with pages indicating coverage in 48 to all 50 states, signaling active expansion. State-by-state therapist listings and nationwide positioning reinforce a broad and growing footprint.

Product Line Growth: Service scope expanded from therapy for older adults to a broader platform that includes behavioral health, advocacy, wellness classes, mind exercises, and AI care agents. This indicates growth beyond the original core offering.

Strong Hiring & Retention: Headcount and hiring activity are depicted as rising quickly, with quarter-over-quarter increases reported by company intelligence trackers and ongoing recruiting across clinical and corporate roles. This workforce build-out supports scaling operations.

Market Expansion: Operations span numerous U.S. cities and key European hubs, and examples such as multi-location laptop programs and a CETF-supported initiative point to activity at broader geographic scale.

Product Line Growth: The offering has evolved into a software-enabled hardware-lifecycle platform with asset tracking, reporting, and APIs, alongside expanded device retrievals covering laptops, phones, tablets, and monitors. This broadening increases addressable use cases.

Strategic Partnerships: Documented collaborations include a CETF–Revivn program cited by the California Public Utilities Commission and large-scale work with Block to repurpose thousands of laptops across global sites. These relationships extend reach and validate operational scale.

Strong Revenue Growth: Revenue is rising sharply, with Q2 2026 at about $71M (+37% YoY) and H1 2026 at $138.8M versus $83.8M in the comparable 2025 period. Sequential gains from late 2025 into 2026 reinforce the growth trajectory.

Profitability: Segment profitability is evident, including roughly $22.9M adjusted EBITDA in Q1 2026 and reported net earnings in 2025. Management guidance pointing to $50–$60M of adjusted EBITDA for 2026 suggests scale efficiencies are emerging.

Strong Market Position & Advantage: Scale and positioning are reinforced by 1.6–1.7 million paying subscribers, rising ARPU, and operation as Upbound’s fastest-growing segment. The acquisition and dedicated segment reporting underscore strategic relevance and competitive standing.

Investor Backing & Capital Strength: Ownership by KIRKBI, the investment company behind LEGO, following its 2022 acquisition provides substantial, long-term capital support for expansion. Public materials characterize the deal as KIRKBI’s first move into digital learning and highlight BrainPOP’s strategic value.

Strong Market Position & Advantage: Public materials indicate presence in over two-thirds of U.S. districts and an estimated 25 million students reached annually, reflecting entrenched classroom adoption. BrainPOP is repeatedly described as a leading platform in K–8 supplemental edtech and a pioneer in animated, curriculum-aligned content.

Product Line Growth: The company has expanded from core videos into offerings like BrainPOP Jr., BrainPOP ELL, and BrainPOP Science, alongside recent additions such as ELA planning tools, connected texts, and enhanced learning activities for 2025–26. Ongoing feature releases and monthly new topics indicate continued investment in product breadth.

Investor Backing & Capital Strength: Funding is described as including a $30M Series B led by Andreessen Horowitz, bringing total backing to about $50M, signaling strong capital support for scaling. Investor commentary highlights conviction in Camber’s execution and claims-data advantage.

Market Expansion: Operations are reported to have broadened from an initial behavioral-health focus into additional care verticals and across all 50 states, alongside rising claims volume and provider reach. Company materials cite millions of claims processed and coverage of large billable amounts.

Strong Hiring & Retention: Hiring activity is ongoing, with the company described in the 51–200 employee range and noting its biggest hiring quarter in 2025. Open roles and expansion of enterprise go-to-market roles indicate continued team scaling.

Market Expansion: The platform’s footprint expanded from 400 participating sites in 2022 to 6,000+ sites by 2026, with presence across 50+ countries and 25+ sponsors. Evidence indicates marketplace adoption more than doubled in 2023 and activity surpassed 100 trials by 2024.

Product Line Growth: The offering broadened from a marketplace into AI-powered patient pre-screening and integrated workflows, with reported operational time savings and enrollment improvements in case studies. Subsequent integrations with CRIO, RealTime eClinical, and eClinPro signal continued platform expansion.

Strategic Partnerships: Relationships include major pharmaceutical organizations (e.g., 16 of the top 30 in 2024 and now 25+ sponsors) and ecosystem deals such as RealTime eClinical (50+ networks representing 2,000+ sites) plus CRIO/eClinPro integrations. These ties appear to extend distribution and enrich data used for site selection and enrollment.

Strong Revenue Growth: ARR is reported to have doubled over the prior year and to be on track for at least another doubling, with profitability cited before the Series A. Hiring alongside revenue growth is described, reinforcing momentum.

Product Line Growth: The platform has expanded beyond basic communications into billing, payroll, enrollment, reporting, subsidy management, and AI tools such as Camber. Current product pages reflect a substantially broader offering than the original scope.

Market Expansion: The company states it serves 5,000+ childcare programs and 500,000+ owners, directors, teachers, and families across all 50 states, and a September 2026 acquisition by Procare underscores expanded reach within the category. Earlier usage metrics and ongoing hiring further illustrate scaling activity.

Investor Backing & Capital Strength: New capital in July 2026—$10M of a planned larger round with an SEC Form D filing—signals renewed financial support, with cumulative funding reported around $52.9M. This underpins ongoing rebuild and expansion efforts.

Market Expansion: Operations span Florida, Ohio, Michigan, Virginia, and Washington, with multiple local offices indicating a substantial multi-state footprint. Reported coverage of 45,000 attributed lives across multiple states points to meaningful scale in these markets.

Strong Hiring & Retention: Company materials and LinkedIn indicate a 201–500 employee range with active recruiting, including peer-support roles. Hiring activity in 2026 aligns with expansion across several states.